InMed Pharmaceuticals Inc. 8-K

What Happened

• On July 6, 2026, InMed Pharmaceuticals Inc. (the Company), its two merger subsidiaries and Mentari Therapeutics, Inc. entered into Amendment No. 1 to the Agreement and Plan of Merger and Reorganization originally dated May 19, 2026.
• The Amendment clarifies the sequencing of the contemplated transactions (name change, redomestication, and any Nasdaq reverse split), adds a mechanism to permit additional pre-closing private placement financing (a “Company PIPE Amendment”), and confirms the parties’ intent that the combined mergers qualify as a reorganization under Internal Revenue Code Section 368(a).

Key Details

• Amendment date: July 6, 2026; original Merger Agreement dated May 19, 2026.
• Company will change its name to “Mentari Therapeutics, Inc.” prior to the Closing Date and will redomesticate from British Columbia to Nevada on the Closing Date (prior to filing the certificate of merger).
• Introduces Company PIPE Amendment to allow potential additional private placement financing of Mentari pre-closing and clarifies how such financings would affect the Exchange Ratio.
• Removes contingency about a possible redomestication to the Cayman Islands and explicitly states the First Merger and Second Merger are intended to be an integrated, Section 368(a) reorganization.
• The Company and Mentari issued a joint press release on July 6, 2026, and a Form S-4 (preliminary joint proxy statement/prospectus) was filed on July 2, 2026.

Why It Matters

• Timing and structure: The sequencing clarifications (name change, redomestication, and reverse split timing) reduce uncertainty about how and when corporate changes will occur at closing.
• Financing and dilution: The Company PIPE Amendment allows for additional private financing before closing; such financings could change the Exchange Ratio and affect existing shareholders’ ownership percentages.
• Tax outcome: Confirmation that the transaction is intended to qualify as a Section 368(a) reorganization signals the parties aim for tax-free treatment for shareholders if conditions are met.
• Next steps for investors: Watch the Form S-4 / proxy materials and any updates on PIPE financings or changes to the Exchange Ratio for details on timing, dilution and vote requirements.